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Abstract
Background: Overactive bladder (OAB) affects the lives of millions of people worldwide and antimuscarinics are the
pharmacological treatment of choice. Meta-analyses of all currently used antimuscarinics for treating OAB found similar
efficacy, making the choice dependent on their adverse event profiles. However, conventional meta-analyses often fail to
quantify and compare adverse events across different drugs, dosages, formulations, and routes of administration. In
addition, the assessment of the broad variety of adverse events is dissatisfying. Our aim was to compare adverse events of
antimuscarinics using a network meta-analytic approach that overcomes shortcomings of conventional analyses.
Methods: Cochrane Incontinence Group Specialized Trials Register, previous systematic reviews, conference abstracts, book
chapters, and reference lists of relevant articles were searched. Eligible studies included randomized controlled trials
comparing at least one antimuscarinic for treating OAB with placebo or with another antimuscarinic, and adverse events as
outcome measures. Two authors independently extracted data. A network meta-analytic approach was applied allowing for
joint assessment of all adverse events of all currently used antimuscarinics while fully maintaining randomization.
Results: 69 trials enrolling 269229 patients were included. Similar overall adverse event profiles were found for darifenacin,
fesoterodine, transdermal oxybutynin, propiverine, solifenacin, tolterodine, and trospium chloride but not for oxybutynin
orally administered when currently used starting dosages were compared.
Conclusions: The proposed generally applicable transparent network meta-analytic approach summarizes adverse events in
an easy to grasp way allowing straightforward benchmarking of antimuscarinics for treating OAB in clinical practice. Most
currently used antimuscarinics seem to be equivalent first choice drugs to start the treatment of OAB except for oral
oxybutynin dosages of $10 mg/d which may have more unfavorable adverse event profiles.
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Introduction
Overactive bladder (OAB) is a widespread chronic illness that
affects the lives of millions of people worldwide at all ages but is
more common in the elderly with a prevalence of up to 31% in
women and 42% in men aged over 75 years [1]. OAB has a major
impact on quality of life, affecting emotional, social, sexual,
occupational, and physical aspects of daily life [2–4], and it is
associated with a greater risk of falls and injuries, including
fractures [5], which may even lead to death. Besides the
debilitating manifestations for patients, OAB also imposes
substantial economic burden as direct annual costs are comparable
to those of other chronic diseases such as dementia and diabetes
mellitus [6].
Non-surgical treatment is the mainstay of therapy for OAB
including lifestyle modifications, behavioral therapy, biofeedback,
bladder training, medication and a combination of these options.
Antimuscarinics are the pharmacological treatment of choice for
OAB. Seven antimuscarincs (darifenacin, fesoterodine, oxybuty-
nin, propiverine, solifenacin, tolterodine, and trospium chloride)
with different dosages, formulations, and routes of administration
are currently used for treating OAB and all have well-established
and similar efficacy (figure S1) shown in systematic reviews [7–13],
so that the selection of the most appropriate depends on their
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16718adverse event profiles. However, over 30 different adverse events
were described and only a few of them were compared
systematically. Moreover, joint assessment of all reported adverse
events of the currently used antimuscarinics is lacking.
In 2004 [14], the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) working group highlight-
ed the importance to interpret quality of evidence in view of trade-
offs between effect and side effects, or desirable and undesirable
consequences of management strategies. However, conventional
meta-analyses often fail to quantify and compare adverse events
across different drugs, dosages, formulations, and routes of
administration, because summaries usually do not use all available
information on reported comparisons and assessment of the broad
variety of adverse events. This is seen as a major impediment when
examining the trade-offs the GRADE working group is calling for.
Recently, new meta-analytic methods – network meta-analysis –
have become available which allow complete assessments across
different drugs. While these methods gained some popularity in
the assessment of treatment effects, their application in side effect
assessment is novel. In view that all antimuscarinics show similar
efficacy, the assessment of side effects alone suffices to provide the
required information for decision-making and evidence grading.
Therefore, we performed a network meta-analysis summarizing
data from all randomized comparative clinical trials assessing
adverse events of all currently used antimuscarinics. Moreover we
propose a way to aggregate the broad variety of reported adverse
events and finally provide adverse event charts for all assessed
medications and dosages allowing straightforward benchmarking
of antimuscarinics for treating OAB in clinical practice.
Methods
Search strategy and selection criteria
This systematic review was done according to the PRISMA
statement [15]. A review protocol was elaborated, which is
available on file with the authors. To identify randomized
controlled trials of antimuscarinics versus placebo (Figure S2),
we started with the recent Cochrane review by Nabi et al. [10] and
a literature search update from June 2005 to November 2007
kindly provided by the Cochrane Incontinence Review Group
according to their previously published search strategy [10]. Head-
to-head comparative trials without a placebo arm were identified
from the two recent meta-analysis by Chapple et al. [12] and by
Novara et al. [13]. In addition, we searched reference lists and
conference abstracts by hand, checked relevant reviews, book
chapters, and contacted manufacturers and trialists. The search
strategies are available on request.
Two investigators (TMK, DL) independently assessed reports
for eligibility. To be included, studies had to be randomized
controlled trials comparing at least one antimuscarinic for treating
OAB with placebo or with another antimuscarinic. All currently
used antimuscarinics were included, i.e. darifenacin, fesoterodine,
oxybutynin, propiverine, solifenacin, tolterodine, and trospium
chloride. Trials with intravesical antimuscarinic administration,
drugs with less direct antimuscarinic effects (such as smooth muscle
relaxants, flavoxate hydrochloride, calcium channel blockers,
potassium channel openers, beta-adrenoceptor agonists, alpha-
adrenoceptor antagonists, prostaglandin synthetase inhibitors, and
tricyclic antidepressants), and drugs no longer used in clinical
practice (such as emepronium bromide or carrageenate, dicyclo-
mine chloride, penthienate, propantheline bromide, and terodi-
line) were excluded. In the case of multiple publications on the
same patients, the most complete report was chosen for each trial.
Data collection
We extracted data in duplicate (TMK, DL) and a third reviewer
(LMB) resolved any discrepancies if the two reviewers disagreed.
We contacted authors of eligible trials that reported insufficient
data and asked them for additional information (Data S1).
Dichotomous data were abstracted into 262 tables. For contin-
uous data, summary estimates per group (means, changes in
means) with measures of variability (standard deviation [SD], 95%
confidence interval [CI]) as available were extracted.
Outcomemeasureswereadverseevents.Afterextraction,adverse
events were classified according to the Common Terminology
Criteria for Adverse Events v3.0 (CTCAE) [16] into 7 categories
(gastrointestinal, ocular/visual, urinary tract related, neurological,
cardiac, respiratory tract related, dermatological adverse events)
and then graded using a visual analogue scale (0=minimum
severity, 10=maximum severity) based on the consensus of 10
independent experts (Table 1). Summarizing different formulations
and routes of administration, antimuscarinics were categorized
based on the daily dose used into the following groups: darifenacin
3.75 mg/d, 7.5 mg/d, 15 mg/d, 30 mg/d; fesoterodine 4 mg/d,
8 mg/d, 12 mg/d; oxybutynin 5 mg/d, 7.5 mg/d, 9 mg/d,
10 mg/d, 15 mg/d, 20 mg/d; oxybutynin transdermal system
(TDS) 1.3 mg/d, 2.6 mg/d, 3.9 mg/d; propiverine 20 mg/d,
30 mg/d, 45 mg/d; solifenacin 2.5, 5 mg/d, 10 mg/d, 20 mg/d;
tolterodine 1 mg/d, 2 mg/d, 4 mg/d, 8 mg/d; trospium chloride
40 mg/d, 45 mg/d, 60 mg/d.
Statistical analysis
We aimed to produce a descriptive model allowing us
summarizing data on adverse events statistically. For each of the
7 adverse event categories and each of the treatment arms, the
number of adverse events, weighted according to the grading
provided in Table 1, were added up and divided by the total
number of patients in the corresponding treatment arm. In this
way, the weighted adverse events per patient in each of the trials
given a specific treatment and dosage were determined. The total
score of adverse events was calculated by adding up these estimates
of the 7 adverse event categories.
For all of the 8 adverse event outcomes (7 adverse event
categories and the total score of adverse events), a linear
regression analysis was performed with drug and dosage as
covariates and using a similar concept as Berlin et al. [17] and as
Hasselblad [18], the event outcome for each single treatment
arm as the dependent variable. To preserve randomization
within each trial, we included a dummy variable for each of the
studies. This dummy variable adjusted for differences in risk
profiles and study setup between trials. The drugs were entered
as indicator variables and the dosages were transformed to a
uniform format by giving value 1 to the currently used starting
dosage and the other dosages the multiplication factor as
compared with this dosage. Thus, when the currently used
starting dosage was 7.5 mg/d and dosages of 3.75 mg/d,
7.5 mg/d, 15 mg/d, and 30 mg/d were investigated, these
values were recoded as 0.5, 1, 2, and 4, respectively. Because
every drug has its own specific dose-adverse event relation,
interaction terms between drug and dosage were added.
Furthermore, the analysis was weighted with the total number
of patients in each treatment arm as a substitute for the inverse
of the variance, and the cluster option was used to take into
account that results within one trial will be correlated. We
investigated the influence of several trial characteristics such as
age, gender, and duration of treatment. This was done by
entering them as an interaction term with treatment into the
model. From this regression model we estimated the difference
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standard clinical practice (i.e. darifenacin 7.5 mg/d, 15 mg/d;
fesoterodine 4 mg/d, 8 mg/d; oxybutynin 10 mg/d, 15 mg/d,
20 mg/d; oxybutynin TDS 3.9 mg/d; propiverine 30 mg/d,
45 mg/d; solifenacin 5 mg/d, 10 mg/d; tolterodine 4 mg/d;
trospium chloride 40 mg/d, 60 mg/d).
All analyses were performed with Stata SE 10.1 (Copyright
1996–2010 StataCorp LP, 4905 Lakeway Drive, College Station,
TX 77845 USA).
Results
We identified 82 reports (Figure S2). Three articles [19–21] not
specifying adverse events, one article [22] not differentiating
adverse events between antimuscarinic and placebo, six articles
[23–28] not discriminating adverse events between different fixed
dosages, and three articles [29–31] only comparing different
releases within the same antimuscarinic and dosage were excluded.
Thus, we finally included 69 trials [32–100] including one report
[66] with two different age strata (Table 2, Data S2). Most trials
had a parallel design (58, 84%) and were placebo-controlled (57,
83%). Overall, the included trials enrolled 26229 patients. The
mean age was 59 years (range 30 to 82), the proportion of women
was 76% (range 0% to 100%) and the mean duration of treatment
was 8 weeks (range 1 to 52 weeks).
We found similar overall adverse event profiles for darifenacin,
fesoterodine, transdermal oxybutynin, propiverine, solifenacin,
tolterodine, and trospium chloride but not for oxybutynin orally
administered when currently used starting dosages were compared
(Figure 1). Orally administered oxybutynin dosages of $10 mg/d
demonstrated the worst adverse event profiles. Darifenacin,
fesoterodine, oxybutynin orally administered, propiverine, and
solifenacin showed a positive and significant dose-adverse event
relation.
Among adverse events, gastrointestinal side effects were most
frequently reported. Only transdermal oxybutynin 3.9 mg/d
showed similar gastrointestinal profiles to placebo (Figure 2).
Ocular/visual adverse events were similar across the various
antimuscarinics when starting dosages were used (Figure S3). This
was also observed for urinary tract related (Figure S4), neurolog-
ical (Figure S5), cardiac (Figure S6), and respiratory tract related
(Figure S7) adverse event profiles. Dermatological adverse events
were insignificant with oral drug administration but a worse profile
was found with transdermal application (Figure S8).
Age, gender, and duration of treatment had no significant
influence on adverse events.
Discussion
Main findings
Our network meta-analysis, which applies a transparent
method, allows direct and indirect comparison of all currently
used antimuscarinics, dosages, formulations and routes of
administration. Moreover, our method provides an easy to grasp
overview of side effects which is important since antimuscarinics
for treating OAB are selected in clinical practice based on the
trade off between drugs’ efficacy and adverse events. The results of
this analysis can be a valuable input for decision analytic models.
Our approach also contributes to a recent call of the GRADE
working group that the strength of evidence should be assessed
considering trade-offs between effect and side effects. Overall
adverse event profiles were similar for all antimuscarinics except
for oxybutynin orally administered when comparing currently
used starting dosages. In addition, except for trospium chloride, we
Table 1. Categorization and grading of adverse events.
Type of adverse events Grading using VAS
Gastrointestinal adverse events
Dry mouth 4
Dry throat 4
Dysgeusia 4
Constipation 4
Diarrhoe 4
Abdominal pain 5
Gastritis 5
Dyspepsia 4
Nausea 5
Vomitus 6
Unspecified gastrointestinal adverse events 5
Ocular/visual adverse events
Dry eye 4
Blurred vision 6
Urinary tract related adverse events
Urinary retention 7
Voiding difficulty 5
Dysuria 5
Urinary tract infection 6
Unspecified urinary tract related adverse events 6
Neurological adverse events
Fatigue 5
Somnolence 8
Sedation 7
Insomnia 6
Confusion 7
Cognitive impairment 7
Depression/lethargy 7
Dizziness/vertigo 5
Headache 5
Cardiac adverse events
Palpitation/tachycardia 5
Hypertension 6
Orthostatic disturbance 6
Fall 8
Respiratory tract related adverse events
Dry nose 3
Cough 4
Nasopharyngitis 4
Sinusitis 4
Upper respiratory tract infection 6
Influenza 6
Dermatological adverse events
Dry skin 2
Erythema/exanthema 4
Pruritus 5
VAS: visual analogue scale (0=minimum severity, 10=maximum severity).
doi:10.1371/journal.pone.0016718.t001
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PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e16718found a positive and significant dose-adverse event relation for the
antimuscarinics.
Findings in the context of existing evidence
In respect to reported adverse events, our data confirm results of
various previous systematic reviews [7–13]. Dry mouth was
consistently the most common complaint [7,8,10,12,13], and this
is in line with our findings that gastrointestinal adverse events were
most frequently reported. In our study, most antimuscarinics had
similar ocular/visual adverse events to placebo when their lower
available dosage was used. This confirms the results of Chapple et
al. [12] regarding blurred vision. Although the inhibitory effect of
antimuscarinics on detrusor muscle contraction could theoretically
cause or aggravate voiding difficulty and urinary retention, urinary
tract related adverse events were not different between anti-
muscarinics and placebo. This is supported by a randomised,
placebo-controlled trial in men with bladder outlet obstruction
showing that antimuscarinic treatment did not adversely affect
urinary function in this high risk group of patients [87]. Central
nervous system (CNS) adverse events are of particular concern as
muscarinic receptors are prominent in the CNS and play an
important role in memory, vigilance, problem solving, stimulus
and response processing [101]. Perry et al. [102] found an
increased occurrence of Alzheimer’s disease (AD) related to a
prolonged antimuscarinic exposure in patients with Parkinson’s
disease raising the concern that chronic antimuscarinic treatment
may increase the risk of AD or accelerate AD pathogenesis.
Notwithstanding the fact that cognitive impairment traditionally
has not been evaluated in antimuscarinics’ trials, CNS adverse
events were rare and we found an overall neurological adverse
event profile for most antimuscarinics similar to placebo in our
study. Cardiac adverse events, particularly the increase of heart
rate and prolongation of the QT interval associated with
polymorphic ventricular tachycardia (or torsade de pointes), can
be serious, and the antimuscarinic agent terodiline was withdrawn
from the market because of an association with QT prolongation
[103]. However, there is no evidence from our data to suggest that
the currently used antimuscarinics increase the risk of cardiac
adverse events when administered at the recommended therapeu-
tic dosages. Respiratory tract related adverse events were
negligible. Dermatological adverse events were insignificant with
oral drug administration but in accordance with previous meta-
analyses [12,13] a worse profile was found with transdermal
application.
Strength and weaknesses
Our network meta-analytic approach provides valuable addi-
tional information to conventional systematic reviews [7–13]. We
performed a joint assessment of all reported adverse events of all
currently prescribed antimuscarinics while by including a dummy
variable, we maintained the comparison of two treatments for
each of the studies. That the overall adverse event profiles of each
antimuscarinic can be summarized in one simple graph (Figure 1)
providing all relevant information at a glance is another strength of
our approach. We believe that this information is useful for health
authorities, policy makers, physicians, and patients alike. As
estimates of the within study variance of the adverse event scores
were not available, a customary network analysis investigating
heterogeneity was not possible. In fact, we assumed heterogeneity
by allowing the outcome parameter to have a variance comprising
the between as well as the within study variance. Eleven studies
used a crossover design. Dependent on the within-subject
correlation, the variance of the within-subject comparison of the
adverse event score will be lower than the between-subject
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PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16718comparison [104]. As the weights are inversely proportional with
the variance, this would mean that the weights of the crossover
studies should be increased. We performed a sensitivity analysis
increasing the weights of studies with a crossover design with a
factor two, showing only minimal differences with the presented
results. Although our figures summarize the adverse event profiles
of the antimuscarinics, it is unclear how predictive the mean values
are for an individual patient.
We categorized the antimuscarinics based on the daily dosage
used in clinical practice, but differences in medication frequency
and formulations were not considered. Only for tolterodine a
reasonable number of studies with both immediate and extended
release formulations were available. However, using our meta-
analytic approach, the influence of the release on the occurrence of
adverse events could easily be investigated by entering an
interaction term with treatment into the regression model. Almost
all studies published are fixed dose trials and we excluded the few
studiesthat didnot clearlyspecifythe doseregarding adverse events.
Thisis an important limitation since in clinical practice the dose of a
drug is often titrated and flexible dose studies tend to report fewer
adverse events. Duration of treatment had no significant influence
on the adverse event profiles but absence of evidence is not evidence
of absence. None of the trials reported whether and how many
patients had two or more adverse events. Therefore, we had to
assume that the occurrence of an adverse event was independent of
the presence of another, although this might be more complex in
clinical reality. Moreover, policy and completeness of adverse event
reporting changed during the last 20 years and differ between the
trials. The impact of this variability on the results is difficult to
determine, but under-reporting of adverse events, particularly in
earlier trials, is likely. It might be argued, that the grading of adverse
eventsshouldbebasedonpatients’ opinion,taking into account that
patients’ and physicians’ values and preferences can differ widely
[105]. Basing the grading system on patients’ preferences would
imply an interview in a representative and extensive sample.
However, this would require an additional study that certainly
should be performed to include patients’ grading in this analysis. As
the decision for a specific antimuscarinic treatment is usually taken
by the physician who is supposed to have a deliberate overview of
the manifestations of a specific adverse event, we decided to base
our grading of adverse events on the consensus of 10 independent
experts.
Figure 1. Overall adverse event profiles (from 69 trials) of different antimuscarinic treatments and dosages per day compared with
placebo (reference line through 0). The orange lines represent the currently used starting dosages (oxybutynin 15 mg/d and trospium chloride
60 mg/d may also be used as starting dosages).# mean, 95% confidence interval, TDS transdermal system, VAS visual analogue scale.
doi:10.1371/journal.pone.0016718.g001
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PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e16718To grade the strength of recommendation, the quality of the
evidence should be assessed. Although only randomized trials are
included (i.e. the highest grade) the quality of evidence should be
downgraded because in most studies the reporting of adverse events
will be impreciseand theprobabilityofreportingbiasis presumable.
Implications for research
We believe that our method provides a useful overview of
benefits and downsides of various medications prescribed in a
particular clinical area. To us, the method is of most value for
researchers commissioned to provide comprehensive summaries
and decision-analytic models to guide decisions of health
authorities such as the Centres of Reviews and Disseminations
(CRDs) in the UK or similar institutions in Germany and the
United States of America. We would like to point out that this
approach is equally applicable to the assessment of treatment
effects. From a decision-making point of view there are new
opportunities that could be explored. For example, adding the
patients’ perspective regarding the burden of adverse events and
the minimum expected beneficial effect could be used as
benchmark criteria against which the optimal regimen could be
selected. Finally, data of the form provided in this article are an
ideal starting point for various cost-effectiveness analyses.
Implications for practice
Although antimuscarinics are generally regarded to be well
tolerated, non-adherence to medication represents a major challenge.
In a community setting, up to 40% of patients may discontinue
antimuscarinic treatment due to adverse events [106]. As shown in
previous systematic reviews [7–13], all currently used antimuscarinics
have similar efficacy for the usually prescribed starting dosages (Figure
S1) and this view is also supported by the NICE guideline [107]. Thus,
differences in adverse event profiles should guide the choice for
treatment. We showed that darifenacin 7.5 mg/d, fesoterodine 4 mg/
d, transdermal oxybutynin 3.9 mg/d, propiverine 30 mg/d, solifena-
cin 5 mg/d, tolterodine 4 mg/d, and trospium chloride 40 mg/d (or
60 mg/d) had similar overall adverse event profiles and seem to be
equivalent first choice drugs to start the treatment of OAB. In case
these first choices are ineffective, dose escalation or changing to
another antimuscarinic appears to be reasonable. Oxybutynin dosages
of $10 mg/d are of questionable value in the current treatment of
OAB because of unfavorable adverse event profiles.
Figure 2. Gastrointestinal adverse events profiles (from 69 trials) of different antimuscarinic treatments with currently used
starting dosages per day compared with placebo (reference line through 0). # mean, 95% confidence interval, TDS transdermal system,
VAS visual analogue scale.
doi:10.1371/journal.pone.0016718.g002
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PLoS ONE | www.plosone.org 8 February 2011 | Volume 6 | Issue 2 | e16718Conclusions
We propose a generally applicable method that summarizes
adverse events in an easy to grasp way using a transparent network
meta-analysis which incorporates all available information from
clinical trials while fully maintaining randomization. Darifenacin
7.5 mg/d, fesoterodine 4 mg/d, transdermal oxybutynin 3.9 mg/
d, propiverine 30 mg/d, solifenacin 5 mg/d, tolterodine 4 mg/d,
and trospium chloride 40 mg/d (or 60 mg/d) seem to be
equivalent first choice drugs to start the treatment of OAB,
whereas oral oxybutynin dosages of $10 mg/d have less favorable
adverse event profiles.
Supporting Information
Figure S1 Efficacy of different antimuscarinics (starting dosages)
compared to placebo (reference line through 0) according to
Chapple et al, Eur Urol 2008;54:543-62 and Staskin et al, Eur
Urol 2009;55:e49-50.
(TIF)
Figure S2 Flow diagram of literature searches and results.
(TIF)
Figure S3 Ocular/visual adverse event profiles (from 45 trials) of
different antimuscarinic treatments with currently used starting
dosages per day compared with placebo (reference line through 0).
# mean, 95% confidence interval, TDS transdermal system, VAS
visual analogue scale.
(TIF)
Figure S4 Urinary tract related adverse event profiles (from 37
trials) of different antimuscarinic treatments with currently used
starting dosages per day compared with placebo (reference line
through 0). # mean, 95% confidence interval, TDS transdermal
system, VAS visual analogue scale.
(TIF)
Figure S5 Neurological adverse event profiles (from 52 trials) of
different antimuscarinic treatments with currently used starting
dosages per day compared with placebo (reference line through 0).
# mean, 95% confidence interval, TDS transdermal system, VAS
visual analogue scale.
(TIF)
Figure S6 Cardiac adverse event profiles (from 22 trials) of
different antimuscarinic treatments with currently used starting
dosages per day compared with placebo (reference line through 0).
# mean, 95% confidence interval, TDS transdermal system, VAS
visual analogue scale.
(TIF)
Figure S7 Respiratory tract related adverse event profiles (from
20 trials) of different antimuscarinic treatments with currently used
starting dosages per day compared with placebo (reference line
through 0). # mean, 95% confidence interval, TDS transdermal
system, VAS visual analogue scale.
(TIF)
Figure S8 Dermatological adverse event profiles (from 21 trials)
of different antimuscarinic treatments with currently used starting
dosages per day compared with placebo (reference line through 0).
# mean, 95% confidence interval, TDS transdermal system, VAS
visual analogue scale.
(TIF)
Data S1 Additional information kindly provided by authors of
eligible trials that reported insufficient data.
(DOC)
Data S2 Database of included trials.
(XLS)
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